Immucell (ICCC) Change in Accured Expenses (2010 - 2025)
Immucell's (ICCC) quarterly Change in Accured Expenses came in at -$22606.0 in Q4 2025, up 7.31% on a YoY basis from -$21065.9 in Q4 2024, and down 116.99% quarter-over-quarter from $133036.0 in Q3 2025.
Powered by 
Analysis
Immucell (ICCC) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Immucell (ICCC) has reported Change in Accured Expenses for 16 consecutive years, with -$22606.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses rose 7.31% year-over-year to -$22606.0; the trailing twelve-month figure through Dec 2025 stood at -$195254.0 (down 153.85% YoY), and the FY2025 full-year result was -$195254.0, down 153.85% from the prior year.
- Change in Accured Expenses slipped to -$22606.0 in Q4 2025 per ICCC's latest filing, from $133036.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $430259.0 in Q2 2024 and bottomed at -$531203.0 in Q1 2025.
- Historically, Change in Accured Expenses has averaged $45586.0 across 5 years, with a median of $8302.0 in 2022.
- The widest YoY moves for Change in Accured Expenses: up 310.35% in 2025, down 2758.67% in 2025.
- Over 5 years, Change in Accured Expenses stood at $367502.0 in 2021, then dropped by 12.31% to $322265.0 in 2022, then retreated by 21.65% to $252488.0 in 2023, then tumbled by 109.66% to -$24389.0 in 2024, then grew by 7.31% to -$22606.0 in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$22606.0, $133036.0, and $225519.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn | - |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn | 142.00 Mn |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn | - |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn | 28.65 Mn |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -22,606.00 |
| Sep 30, 2025 | 133,036.00 |
| Jun 30, 2025 | 225,519.00 |
| Mar 31, 2025 | -531,203.00 |
| Dec 31, 2024 | -24,389.00 |
| Sep 30, 2024 | -63,244.00 |
| Jun 30, 2024 | 430,259.00 |
| Mar 31, 2024 | 19,980.00 |
| Dec 31, 2023 | 252,488.00 |
| Sep 30, 2023 | -86,311.00 |
| Jun 30, 2023 | 249,324.00 |
| Mar 31, 2023 | -258,506.00 |
| Dec 31, 2022 | 322,265.00 |
| Sep 30, 2022 | -3,376.00 |
| Jun 30, 2022 | 168,728.00 |
| Mar 31, 2022 | -146,003.00 |
| Dec 31, 2021 | 367,502.00 |
| Sep 30, 2021 | 150,000.00 |
| Jun 30, 2021 | -230,089.00 |
| Mar 31, 2021 | -41,653.00 |